Refine by
Disease Research And Drug Development Articles & Analysis
198 news found
Creative BioMart, a biotechnology company focused on protein-related research solutions, has recently upgraded its epitope mapping service to better support researchers in therapeutic antibody development, vaccine design, and immunogenicity studies. The updated platform integrates multiple experimental approaches with customizable strategies, enabling more accurate identification of antibody ...
Diabetes mellitus, a chronic condition characterized by elevated blood sugar levels, affects millions worldwide and poses serious health risks including cardiovascular disease, kidney failure, and nerve damage. As the prevalence of diabetes continues to rise, there is an urgent need for advanced research models that can accurately simulate the ...
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics has announced the launch of its Zika Virus Animal Model services for scientists to understand the complex mechanisms of Zika virus infection and develop effective countermeasures. These models are valuable tools in the research and development of vaccines and therapeutics against this emerging ...
Protheragen is proud to release the launch of its comprehensive vaccine development solutions tailored to advance research and development in the field of infectious diseases. This strategic initiative aims to accelerate the creation of effective vaccines to combat emerging and re-emerging infectious threats. Infectious diseases are disorders caused by organisms — such as bacteria, ...
Protheragen, a dedicated preclinical research service provider specializing in rare diseases, announces its comprehensive diagnostic development services aimed at empowering researchers in the realm of rare disease research and drug development. ...
Ace Therapeutics is proud to announce the launch of its cardiovascular disease model development services, aiming to empower researchers and pharmaceutical companies with advanced tools and models to accelerate the study of cardiovascular diseases and drug discovery. ...
Over the past decade, Alfa Chemistry has shown abundant expertise in the rapidly growing dietary supplements sector. To cater to the rising demand in this field, the company decided to add lecithin, omega fatty acids, phytosterol, and antioxidants to its already versatile functional ingredient offerings. Fully aware of the importance of lecithin in the dietary supplements industry, Alfa Chemistry ...
CD Genomics, a trailblazer in genomics and epigenomics research, is proud to announce the launch of MeRIP Sequencing, a cutting-edge technology revolutionizing the analysis of m6A modifications on RNA molecules. This breakthrough method promises to provide researchers with unparalleled insights into the dynamic world of epigenetic modifications, setting a new standard in precision ...
Their use is crucial in unraveling the complexities of related diseases and developing effective treatments. By employing appropriate behavioral research methods, scientists can establish a solid foundation for studying these diseases, leading to invaluable insights and potential breakthroughs in patient care. ...
As several gene therapy approvals for rare disease treatment gain steam in 2023, a comprehensive set of gene therapy development solutions is released to pave richer avenues for rare disease research. ...
All these APIs are essential for the development of effective drugs to meet various medical needs. Amino Acid SeriesAmino acids are the building blocks of proteins and are critical for several physiological processes. CD Formulation offers a variety of amino acids and amino acid derivatives, including DL-Alanine (CAS 302-72-7), Glycylglutamine (CAS 13115-71-4), ...
CD Genomics, a renowned provider of genomics services, is proud to unveil its cutting-edge Whole Exome Sequencing (WES) service. This offering provides researchers and clinicians with a powerful tool to investigate the exome, shedding light on the intricacies of the human genome and propelling our understanding of genetic diseases. ...
Mass spectrometry is a powerful analytical tool that plays a key role in drug development by providing accurate, reliable, and timely data for successful clinical trials, disease research, drug development, and target discovery experiments. ...
European Commission granted approval of Nubeqa (darolutamide) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) Approval is based on Phase III ARASENS trial data The European Commission has granted marketing authorization in the European Union (EU) for Nubeqa™ (darolutamide), an oral androgen receptor inhibitor (ARi), plus androgen deprivation ...
ByBayer AG
Airfinity announces today the launch of Airfinity IDA (Infectious Disease Analytics) 360, a new platform that will provide a comprehensive overview of vaccine and therapeutics candidates across the full infectious disease landscape. Airfinity IDA 360, a first-of-its-kind product in the health analytics market, will be a centralised source of competitive intelligence, providing clear and near ...
High demand seen for effective disease management platform for second most common cancer in Singaporean men NEW YORK and SINGAPORE, March 28, 2022 /PRNewswire/ -- miR Scientific, a New York-based healthcare company dedicated to transforming global cancer management, and Leonie Hill Capital, a Singapore-based organization focused on large-scale, sophisticated healthcare access and distribution, ...
Metabolomics, a division of Creative Proteomics, is dedicated to providing cutting-edge LC-MS-based metabolomics services for biomedical research institutions as well as biotechnological and pharmaceutical companies. Creative Proteomics Metabolomics announced the launch of the Gut Microbiota Metabolomics Service, aiming to detect the dynamic changes in enterobacterial metabolites and clearly ...
CHMP recommendation is based on Phase III data, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5% compared to ADT with docetaxel alone, with similar overall rates of adverse events between study arms European Commission decision on granting a marketing authorization is anticipated within ...
ByBayer AG
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced that the U.S. ...
Phase 1 trial of tau-targeting lead program planned to begin in 3Q22 Funding will also support the characterization of the Company’s second-generation assets Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, announced that the Company has recently closed an ...